CompletedNCT00215579
Long-acting risperidone for people with psychosis who miss oral medicines
About this title
Read the official source — NCT00215579Medication studyAges 18–65United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- ButnerSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateApril 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 64
- Sponsor
- Duke University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00215579
- Official title
Show the full official title
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Butner
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Duke University, a university.
Did this study involve medication?
Yes. The study involved medication, including Depot Risperidone Microsphere (Consta).
Who was this study for?
Listed age limits: 18 years to 65 years.
